JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET …

2021年3月15日 · A chemical combinatorial screening of JQ1 with around 1900 compounds aimed at finding effective small molecule combination therapies with BETi revealed PI3K inhibitors to …

2023年5月1日 · JQ1: JQ1 was the first and most well-characterized BRD4 inhibitor reported in 2010. JQ1 is a thieno-triazolo-1,4-diazepine that displaces BET proteins from chromatin by …

2020年3月10日 · Our results suggest that BET protein inhibitor JQ1 prohibits the malignant progression of GC cells by downregulating chromatin accessibility and inactivating …

2016年6月13日 · JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic …

2018年9月1日 · JQ1 as a first-in-class potent and selective inhibitor of the BRD4 signaling pathway is widely used for tumor biology studies. It was found that JQ1 could potently reduce …

2024年4月1日 · JQ1, a small molecule inhibitor of BRD4, is superior in synergistic treatment with PDT. The nanocomplex exhibited enhanced immunotherapeutic effects and inhibited distant …

In our study, we found that JQ1 can inhibit the expression of NSC markers Nestin and ciliary neurotrophic factor and promote GSC differentiation to astrocytes under proliferative …

JQ1 is a member of the class of thienotriazolodiazepines that is the tert-butyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. …

JQ1 induces adipose tissue wasting without affecting skeletal muscle mass and function. Timeline and schedule of (A) long-term experiment: mice were exposed for 20 weeks to high fat diet …

2021年1月1日 · JQ1 is a BRD4 inhibitor that has been widely studied in cancer research. It displaces BET bromodomains from chromatin and interferes with BRD4 function, leading to …

JQ1 may be a new drug for oral squamous cell carcinoma treatment. The present study aimed to evaluate whether bromodomain 4 (BRD4) is expressed in Cal27 cells and to assess the effect …

2019年7月16日 · JQ1 is a bromodomain inhibitor, which selectively binds to the amino-terminal twin bromodomains of BET proteins 10. JQ1 treatment displaces BRD4, inhibiting its ability to …

2016年12月2日 · JQ1 is a small molecule that interferes with transcriptional regulators, such as BRD4, by preventing them from interacting with acetylated regions of the genome and thus …

2014年1月23日 · JQ1, a chemical compound that inhibits MYC expression is therapeutically effective in preclinical animal models in midline carcinoma, and Burkitt’s lymphoma (BL). Here …

2022年10月11日 · Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription …

The selective small molecule inhibitor JQ1, which binds competitively to bromodomains, has been reported to exhibit anti‑proliferative effects in various types of cancer.

2010年9月24日 · Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.

2025年2月1日 · JQ1 induces adipose tissue depletion preserving skeletal muscle mass and strength. JQ1-induced adipose tissue loss does not alter systemic glucose and improves lipid …

In the present study, we investigated the effects of JQ1, a bromodomain and extraterminal-bromodomain inhibitor, on cell growth, and messenger RNA (mRNA) and protein levels of PD …